Printer Friendly

Moxifloxacin for TB.

Moxifloxacin had activity similar to rifampin for the treatment of pulmonary tuberculosis in a recent study and may have a place as part of a short-course treatment regimen, said Dr. Roly D. Gosling of Royal-Free and University College Medical School, London, and colleagues.

In 43 patients with pulmonary TB who were randomized to receive treatment with isoniazid, moxifloxacin, or rifampin, the mean time to kill 50% of bacilli was significantly different in the isoniazid group (0.46 days) from both the moxifloxacin (0.88 days) and rifampin (0.71 days) groups, but did not differ significantly between the moxifloxacin and rifampin groups. Early bactericidal activity (drop in sputum viable count during the first 2 days of treatment) was greatest in the isoniazid group (0.77 colony-forming units [cfu]/mL); this was significantly greater than in the rifampin group (0.28 cfu/mL), but dial not differ significantly from the 0.53 cfu/mL drop in the moxifloxacin group (Am. J. Respir. Crit. Care Med.168[11]:1342-45, 2003).
COPYRIGHT 2004 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Clinical Capsules
Author:Worcester, Sharon
Publication:Internal Medicine News
Date:Feb 1, 2004
Previous Article:Environmental E. coli.
Next Article:HBV and kidney disease.

Related Articles
Bronchitis exacerbations may respond better to short course of moxifloxacin: compared with standard regimens.
TB Alliance advances two drugs in clinical trials.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters